Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study will determine the highest dose of KW-2450 in combination with lapatinib and
letrozole that can be administered safely to subjects with advanced or metastatic breast
cancer and to evaluate its effectiveness.
This study was terminated in Phase 1 and never proceeded to the Phase 2 portion of the study.